anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will be an open label (all volunteers and study staff know the identity of the assigned treatment), single-dose, multicenter (the study will be conducted at more than one center), parallel-group study (each group of volunteers will be treated at the same time) to assess the pharmacokinetics and pharmacodynamics of canagliflozin (a drug currently being investigated for the treatment of type 2 diabetes mellitus) in volunteers with varying degrees of kidney function. The study will consist of 3 phases: a screening phase, an open-label treatment phase, and an end-of study (or follow-up) phase. Volunteers will be assigned to 1 of 5 groups (depending on kidney function): group 1 will have normal kidney function; group 2 will have mild kidney impairment; group 3 will have moderate kidney impairment; group 4 will have severe kidney impairment; and group 5 will comprise volunteers requiring hemodialysis. Volunteers in groups 1 through 4 will receive a single dose of canagliflozin on Day 1. Volunteers in group 5 will receive a single dose of canagliflozin following dialysis and then, approximately 10 days later, they will receive a second dose before dialysis. Volunteers in groups 1 through 4 will participate in the study for 27 days. Volunteers in group 5 will participate in the study for 40 days.
The present invention discloses the novel pharmaceutical application of scutellaria stem-leaf total flavonoids and the scutellarin thereof, i.e. the stem and leaf of scutellaria are adopted to prepare an extraction with a total flavonoid content of not less than 50% as a medicament for treating dementia and the extraction with a scutellarin content of not less than 98% as a medicament for treating dementia. The two medicaments and the agents thereof can represent the shapes of tablets, capsules, dripping pills, oral medicinal liquids, injections, etc. The application using the special polyhydric structure of scutellaria stem-leaf total flavonoids has the characteristics of strong reducibility and antagonism towards free radicals. The obvious medical care effect obtained by perennial animal experiment researches can prove that the medicaments have reliable anti-dementia functions. The medicaments have the advantages of obvious pathology function, positive clinic curative effect, safety, low toxicity, plentiful resource and low cost, and thus, the medicaments have integral effects exceeding that of an existing anti-senile dementia medicament.
PURPOSE: Osteosarcoma (OS) is a primary bone tumor with high malignancy and poor prognosis. Ferroptosis plays a crucial role in OS. This study aimed to evaluate the effects of Ankyrin 1 (ANK1) on OS and to investigate its specific mechanisms.
METHODS: Microarray datasets related to "osteosarcoma" were selected for this study. Relevant hub genes in OS were identified through bioinformatics analysis. Transfected U-2OS and MG-63 cells were used for in vitro experiments. The effects of ANK1 overexpression on cell viability, migration, and invasion were determined through CCK-8, wound healing, and transwell assays. An OS mouse model was established for the in vivo experiments. Hematoxylin-eosin staining and immunohistochemistry were conducted to observe the histological effects of ANK1 overexpression on mouse tumors. TUNEL staining was performed to evaluate apoptosis in mouse.
RESULTS: There were 159 common differentially expressed genes in the GSE16088 and GSE19276 datasets. The hub genes ANK1, AHSP, GYPB, GYPA, KEL, and ALAS2 were identified. Pan-cancer analysis verified that ANK1 was closely associated with cancer prognosis and immune infiltration. Furthermore, ANK1 overexpression inhibited the proliferation, migration, and invasion of OS cells and promoted ferroptosis, while ferroptosis inhibitor (fer-1) weakened these effects. Moreover, ANK1 overexpression suppressed tumor growth, promoted apoptosis, reduced the number of Ki67 positive cells, and elevated the number of caspase-3 positive cells in vivo.
CONCLUSIONS: ANK1 is a prognosis biomarker of OS that can alleviate the progression of OS by promoting ferroptosis.
Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
PURPOSE OF REVIEW: To explore the contributions of recent qualitative literature in progressing understanding of the experiences of cancer cachexia, and its management, from the perspectives of patients and unpaid/family carers.
RECENT FINDINGS: Challenges with conducting everyday activities, maintaining independence, and continuing usual roles within the family are sources of distress. Patients and carers value individualization, flexibility, and carer involvement in physical activity/exercise interventions. In psychosocial/educational interventions that were positively perceived, the opportunity to talk about cachexia was appreciated, leading to improved health literacy, awareness about nutrition, and relationships with food. However, the general patient and carer experience around clinical acknowledgement and management of cachexia remains poor.
SUMMARY: Eating-related distress and conflicts, lack of understanding about cachexia, and the visibility of weight loss remain recurring themes amongst literature on experiences of cancer cachexia. Studies exploring preferences for, and experiences of, interventions have primarily focused on physical activity or exercise. Psychosocial/educational and physical activity/exercise interventions are valued and perceived to alleviate some of the key quality of life issues amongst patients with cancer cachexia and their unpaid/family carers.
The technology disclosed herein relates to learning and applying background patient similarity. A plurality of template similarity functions (118) may be provided (602). Each template similarity function may compare a respective feature subset of the query entity feature vector with a corresponding feature subset of the candidate entity feature vectors. A composite similarity function (120) may be provided (604) as a weighted combination of the respective outputs of the template similarity functions. A plurality of tagged entity vectors may be provided (606) as background training data. An approximation function may be applied (608) to approximate the first background token for each respective token's entity vector. A first background-specific composite similarity function may be trained (610) based on the composite similarity function by: learning first background weights for the plurality of template similarity functions using a first loss function based on an output of the application of the approximation function to the first background training data.
The training arm participates in the robotic suturing simulation curriculum, a "proficiency" curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average.
According to an embodiment, a computer-implemented method for identifying islands (303) of interest on a 3D dental model (100, 300) is disclosed. The method comprising the steps of receiving at least a first dental 3D scan data of a subject, generating the 3D dental model (100, 300) based on the received at least first dental 3D data of the subject. Method further comprises a step of identifying a plurality of regions on the 3D dental model (100, 300), each region of the plurality of regions indicating presence of at least one dental condition. A severity factor value for each region of the plurality of regions is determined, the severity factor value indicating a level of severity of the at least one dental condition. The method further comprises step of marking, on the 3D dental model (100, 300), each region of the plurality of regions with a visual indicator, wherein the visual indicator is selected based on the determined severity factor value for said region. A plurality of islands (303) is then obtained by grouping the plurality of regions on the 3D dental model (100, 300) such that each island (303) comprises neighboring regions indicating presence of the at least one dental condition. The 3D dental model (100, 300) is then displayed.
The participants in the control group will receive no intervention. However, the investigators will provide the control group with a copy of the booklet that includes 2020 USDA dietary guidelines for a healthy diet for young children. This will enable the investigators to see if the multi-component education intervention (stated above) is more effective on behavior changes than the written booklet in the control group.
Systems and methods for determining corresponding locations of points of interest in a plurality of input medical images are provided. A plurality of input medical images comprising a first input medical image and one or more additional input medical images is received. The first input medical image identifies a location of a point of interest. A set of features is extracted from each of the plurality of input medical images. Features between each of the sets of features are related using a machine learning based relational network. A location of the point of interest in each of the one or more additional input medical images that corresponds to the location of the point of interest in the first input medical image is identified based on the related features. The location of the point of interest in each of the one or more additional input medical images is output.
FIELD: medicine, in particular, pharmaceutical industry. SUBSTANCE: species contains motherwort, sage, beggarticks, nettle, dog rose, wild camomile, foxberry leaves, eucalyptus, tansy, yarrow and calendula in preset ratio. Species may be used as fitotea as biologically active additive for persons suffering from disturbances of gastroenteric tract, urinary tracts and dermatic diseases. Species produces detoxicating effect and promotes clearance of liver, kidneys and skin. It also has antimicrobic and antiinflammatory action, reduces time for positive effect and extends remission. EFFECT: higher detoxicating effect.
Immunotherapy with immune checkpoint-inhibitors is standard treatment for patients with melanoma. However, in about 15% of patients treated with Ipilimumab a grade 3-4 colitis will occur. In programmed cell death protein 1 (PD1) inhibitors colitis is also seen as adverse event, although less prominent. We want to find a good predictive biomarker to select patients that are prone to colitis.So far no test is available that might be predictive whether a patient will develop a grade 3-4 colitis.

The study will consists of four parts: 1.) to identify a genetic profile associated with ipilimumab-induced colitis, 2.) to identify predictive (serum or fecal) biomarkers for ipilimumab-induced colitis, 3.) to study the tissue of ipilimumab-induced colitis and 4) to study the role of the gut microbiome in the development of colitis. Patients are able to participate in one, or more parts of the study.
1340518 Medicated ophthalmic compositions BURTON PARSONS CHEMICALS Inc 30 Nov 1970 33488/73 Divided out of 1340516 Addition to 1340516 Headings C3F and C3R [Also in Division A5] An ophthalmic composition comprises an aqueous solution of an ethylene oxide polymer having a molecular weight of at least 100,000 in an amount sufficient to provide a viscosity up to 30,000 cp, at least one ophthalmic medicament and at least one water-soluble ophthalmically acceptable cellulosic derivative. The cellulosic derivative may be methyl-; hydroxymethyl-; hydroxypropyl-; carboxymethyl-; hydroxypropylmethyl celluloses or mixtures thereof. Optionally the composition may contain 500-5000 wt. per cent of a polyalkylene glycol, preferably poly(ethylene glycol). The ophthalmic medicament may be a cortisone, neomycin sulphate, bacitracin, penicillin, a sulpha derivative, scopolamine hydrobromide, epinephrine bitartrate, a derivative of phenylephrine, neostigmine bromide, a salt of pilocarpine, idoxuridine, 2,3-diemthyl-1-phenyl-3-pyrazolin-5- one, naphthazoline hydrochloride and antazoline phosphate. The pH may be controlled by eyecompatible buffers, e.g. phosphoric acid and sodium borate or mono-sodium and di-sodium phosphate, and may further comprise eye compatible biocides, non-ionic surfactants and, as a detoxicant and demulcent lubricant, polyvinyl pyrrolidone.
Background. Dietary interventions and cohort studies of tree nuts lowering glucose levels for diabetes suggest a possible effect with walnuts. Objective. To examine the associations between walnut consumption and diabetes risk through data from the National Health and Nutrition Examination Survey (NHANES). Methods. NHANES survey data for 1999 through 2014 was pooled for adults with 24 hour recall dietary data. Risk of diabetes was based on self-report, medication use, fasting plasma glucose levels, and hemoglobin A1c (HbA1c) levels. Individuals were characterized as reporting consumption of walnuts, mixed 'nuts', or no nuts.
The family Papillomaviridae includes a plethora of viral species infecting virtually all vertebrates excluding amphibians, with astonishing impact on human and animal health. Although more than 250 species have been described in humans, the total number of papillomaviruses (PVs) discovered in animals does not reach up to this number. In animals, PV infections are mostly asymptomatic or can cause variable clinical conditions ranging from self-limiting papillomas and other cutaneous and mucosal benign lesions to cancer. Most of animal PV types have been discovered in cattle, dogs, horses, and cats with other farm host species remaining overlooked. In particular, the number of PV types so far identified in sheep is limited. This paper comprehensively reviews ovine PVs features, including viral taxonomy and evolution; genome organization; viral tropism and pathogenesis; macroscopical features and histopathological patterns, as well as available diagnostics tools. Data are critically presented and discussed in terms of impact on veterinary and public health. The development of future dedicated research is also discussed.
Recently, there has been an emphasis on keeping the study of anatomy using donor material confined to the domain of medical and allied healthcare professionals. Given the abundance of both accurate and inaccurate information online, coupled with a heightened focus on health following the COVID-19 pandemic, one may question whether it is time to review who can access learning anatomy using donors. In 2019, Brighton and Sussex Medical School (BSMS) obtained a Human Tissue Authority Public Display license with the aim of broadening the reach of who could be taught using donor material. In 2020, BSMS received its first full-body donor with consent for public display. Twelve workshops were delivered to student groups who do not normally have the opportunity to learn in the anatomy laboratory. Survey responses (10.9% response rate) highlighted that despite being anxious about seeing inside a deceased body, 95% felt more informed about the body. A documentary "My Dead Body" was filmed, focusing on the rare cancer of the donor Toni Crews. Viewing figures of 1.5 million, and a considerable number of social media comments highlighted the public's interest in the documentary. Thematic analysis of digital and social media content highlighted admiration and gratitude for Toni, the value of education, and that while the documentary was uncomfortable to watch, it had value in reminding viewers of life, their bodies, and their purpose. Fully consented public display can create opportunities to promote health-conscious life choices and improve understanding of the human body.
<P>PROBLEM TO BE SOLVED: To provide an anticancer agent having safe and excellent anticancer activity and producible by a simplified production process, and to provide a food and drink.  <P>SOLUTION: The anticancer agent contains a cultured product obtained by culturing a mycelium of Basidiomycete and/or Ascomycete in a medium prepared from a raw material containing algae, or an extract prepared from the cultured product as an active ingredient. Chlorella and/or Spirulina is preferable as the algae, and shiitake mushroom or Ganoderma lucidum is preferable as the Basidiomycete and/or the Ascomycete. The cultured product is preferably collected as an extract obtained by autolysis by an enzyme contained in the mycelium of the Basidiomycete and/or the Ascomycete. The anticancer agent can be added to various kinds of foods and drinks.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to piperlongumine, a derivative thereof, and a synthesizing method thereof. The piperlongumine and the derivatives thereof are synthesized by making a variety of amides/lactams react with a variety of acid chlorides of 3,4,5-trimethoxycinnamic acid. In addition, anti-inflammatory effect is tested in RAW264.7 macrophage induced by LPS with respect to the compounds. The piperlongumine of the compounds shows maximum inhibition activity (91.3%) and has cytotoxicity. A compound 3 having alpha, beta-unsaturated butyrolactam does not show cytotoxicity, and has a significant inhibition effect of 64.8%. An amide/lactam region connected to an alpha, beta-unsaturated cinnamoyl group having the chain length of at least three carbons exhibits a strong anti-inflammatory activity without cytotoxicity.
PURPOSE: To obtain a dermal preparation for external use excellent in keratin moisture retention, anti-itching effect and antiinflammtory effect comprising urea, diphenyhydramine and glycyrrhetinic acid. CONSTITUTION: (A) 0.1-1-%.wt. of diphenhydramine as an antihistaminica and (B) 0.1-10%.wt. of glycyrrhetinic acid as an anti-inflammatory agent are formulated to (C) a dermal preparation containing 1-40%.wt. of urea. Diphenhydramine and glycyrrhetinic acid are used at the ratio of 10/1-1/10. This preparation can further contain a higher alcohol, a water-soluble polymer, a water-soluble thickener and an oily component as other components appropriately and adjusted to pH6-9. Urea is stabilized in the formulation by adding diphenhydramine and glycyrrhetinic acid.
ADAPT-ENRICH will supplement an on-going program (ADAPT) which consists of 2 additional recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will be recruited from an initially asymptomatic population that have been referred for clinically indicated breast biopsy based on suspicious DBT screening breast imaging results. Subjects will undergo a DBT mammogram prior to biopsy. If FFDM was not performed within 30 days, subjects will also undergo FFDM prior to biopsy. Results of biopsy(ies) and histopathology, including lesion characteristics, will be recorded and considered as truth if positive for cancer status. Subjects with negative or benign histological findings will be followed for approximately one year (10-16 months) by FFDM and any additional standard of care practice.
This is a pilot feasibility study designed to investigate the alterations in the gut microbiome that occur during the course of treatment for colorectal cancer (CRC). Three patient cohorts will be followed. Cohort A: patients treated with oral fluoropyrimidine CAP as part of standard of care (SOC) chemotherapy. Cohort B: patients treated with TAS-102 including those receiving it in combination with Y-90 radioembolization as part of a clinical trial. Cohort C: patients receiving CAP plus immunotherapy (pembrolizumab) and bevacizumab as part of a clinical trial. Investigators will replace participants as needed to ensure a minimum of 10 evaluable participants per cohort (or minimum total of 30 evaluable patients). Evaluable participants are defined as patients with two analyzable stool samples including a baseline sample and at least one on-treatment sample to be used in endpoint analysis
Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
The invention discloses misoprostol vaginal pellicle which is prepared from misoprostol hydroxypropyl methyl cellulose dispersion and a film-forming material. The film forming material comprises natural high molecular substance and/or synthetic high molecular material; the natural polymer is starch, dextrin, cellulose, gelatin, acacia, agar, alginic acid or rhizoma bletilla polysaccharide; the synthetic polymer material is polyvinyl alcohol compound, acrylic copolymer or cellulose derivative. The preparation method comprises the following steps: dissolving the film-forming material with water respectively, adding misoprostol hydroxypropyl methylcellulose dispersion, mixing, centrifuging to remove bubbles, coating to form film, repeatedly freezing and thawing for crosslinking, and drying. The misoprostol vaginal membrane has good effects of softening cervix uteri and promoting uterine contraction. The preparation is used for local application, has good patient compliance and low cost, and has remarkable advantages. The product is safe, effective and convenient to use, and has good drug stability; the preparation method of the invention is simple and easy.
The present invention relates to a preparation technology of a tinea-eliminating medicine capable of forming a thin film, which is a preparation method of an external application ointment for treating mycotic infection skin tinea. The preparation technology of a tinea-eliminating medicine capable of forming a thin film comprises: clotrimazole is used as a main medicine and dissolved in a mixed solvent composed of dimethyl sulfoxide, ethyl alcohol and ethyl acetate, and then, the clotrimazole, the mixed solvent and a mixture of a sodium alginate solution, carbamide and glycerin are uniformly mixed. The present invention has the advantages of simple technology, little energy consumption and convenient operation. The prepared tinea-eliminating medicine capable of forming a thin film has therapeutic effects on various skin diseases, and the effectiveness ratio reaches 98%. The tinea-eliminating medicine capable of forming a thin film has the advantages of quick medicine release, strong skin permeating property, quick therapeutic effect, no irritation and difficult desquamation. Clothes can not be polluted because the tinea-eliminating medicine is in a film shape after being smeared.